SLU-PP-332 vs 5-Amino-1MQ: How These Two Research Compounds Compare

SLU-PP-332 and 5-amino-1MQ are both research-only compounds studied for metabolic effects, but they work through completely different biological pathways. SLU-PP-332 is an estrogen-related receptor (ERR) agonist often described as an exercise mimetic, while 5-amino-1MQ is an NNMT inhibitor that affects NAD+ metabolism and fat cell activity. Neither compound is FDA-approved for human use, and no head-to-head human study of SLU-PP-332 vs 5-amino-1MQ exists.

What Each Compound Actually Is

SLU-PP-332 was developed by researchers at Saint Louis University as a pan-agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ. Those receptors help control mitochondrial biogenesis and oxidative metabolism, which is why the molecule is commonly described as an exercise mimetic. It is a laboratory reference chemical with no approved human product.

5-amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase, or NNMT. NNMT activity influences NAD+ availability and the cell's methylation balance, and elevated NNMT has been linked to obesity and insulin resistance in animal models. Like SLU-PP-332, 5-amino-1MQ is sold strictly for research purposes.

SLU-PP-332 vs 5-Amino-1MQ: Head-to-Head Comparison

Feature	SLU-PP-332	5-Amino-1MQ
Primary target	ERRα/β/γ (agonist)	NNMT (inhibitor)
Main research interest	Exercise mimicry, endurance, mitochondrial function	NAD+ metabolism, fat mass, glucose tolerance
Key animal findings	Greater running endurance and fat oxidation in mice	Reduced fat mass and better glucose tolerance in obese mice
Human clinical data	None published	None published
FDA approval status	Not approved for human use	Not approved for human use
Reported pharmacology	Short half-life and low oral bioavailability in rodents	Active when given orally in rodent diet studies
Typical research forms	Powder for injection or oral gavage	Powder for diet, oral, or injectable use

The practical takeaway from this table is simple: SLU-PP-332 and 5-amino-1MQ do not act on the same receptor, so comparing them is closer to comparing two different tools than two versions of the same product.

What the Research Actually Shows

Both compounds have produced interesting preclinical results, and both remain far from clinical use.

SLU-PP-332

• In mouse studies, SLU-PP-332 increased endurance capacity and fatty acid oxidation while reducing fat mass.
• In rodent heart failure models, ERR agonism improved cardiac function and exercise tolerance.
• Newer analogs were developed specifically to address the compound's short half-life and poor oral absorption.

Most of the slu-pp-332 benefits discussed online are extrapolated from these rodent experiments. SLU-PP-332 has never been tested in a controlled human trial, so its effects on human body composition and performance are unknown.

5-Amino-1MQ

• Diet-induced obese mice treated with 5-amino-1MQ lost fat mass and showed improved glucose tolerance without reducing food intake.
• The compound raised NAD+ levels in studied tissues and limited fat cell expansion in cell culture.
• All reported outcomes come from rodent or in vitro work.

No published study has measured 5-amino-1MQ outcomes in humans. Claims that it produces rapid fat loss in people are not supported by clinical evidence.

Dosing, Forms, and Administration in Research Settings

There is no established human dose for either compound. Numbers shared in forums come from rodent studies with different pharmacokinetics, and animal doses rarely translate directly to people.

Anyone researching the slu-pp-332 oral vs injection question should note that published mouse studies used injection or oral gavage, and that the compound's short half-life limits how long a single dose stays active. For 5-amino-1MQ, animal work delivered the compound through the diet or by injection, so any 5-amino-1mq subcutaneous injection dosage discussed online describes a research protocol rather than a validated human schedule.

Because no pharmacokinetic data exists in humans, questions about timing, cycling, and stacking have no reliable answer. Self-experimentation with unapproved compounds carries real risk, including dosing errors and unknown drug interactions.

Safety, Legality, and Sourcing

SLU-PP-332 and 5-amino-1MQ are sold as research chemicals, usually with a "not for human consumption" label. The FDA has not evaluated either compound for safety, purity, or effectiveness, and products sold online are not guaranteed to match their stated identity or purity.

People searching for 5-amino-1mq where to buy should understand that this market is loosely regulated. Certificates of analysis vary widely in quality, and injectable products carry extra risks such as contamination, endotoxins, and sterility failures.

Human side effects are unknown for both compounds. Potential concerns include unpredictable interactions with prescription medications, unclear long-term effects, and unanswered questions about hormonal signaling with ERR agonists. Anyone considering these compounds should consult a licensed healthcare professional first.

Bottom Line: Which One Fits Your Research Question?

SLU-PP-332 and 5-amino-1MQ target different pathways, so the better choice depends on the biology a researcher wants to study. If the focus is mitochondrial function, endurance, or exercise mimicry, SLU-PP-332 is the more relevant molecule; researchers comparing slu-pp-332 vs mots-c are asking a similar question about metabolic activators that act through different mechanisms.

If the focus is NNMT biology, NAD+ status, or adipocyte metabolism, 5-amino-1MQ is the more relevant molecule. Neither compound is a proven weight-loss drug, neither has human safety data, and neither should be presented as a treatment for any medical condition.

COMMON QUESTIONS

Frequently Asked Questions

Is SLU-PP-332 or 5-amino-1MQ better for fat loss?

Neither compound has been tested for fat loss in humans, so there is no evidence that one is better than the other. In mice, SLU-PP-332 increased endurance and reduced fat mass, while 5-amino-1MQ reduced fat mass and improved glucose tolerance. Both remain unapproved research chemicals and should not be used as weight-loss products.

Are SLU-PP-332 and 5-amino-1MQ legal to buy in the United States?

Both are sold as research chemicals rather than dietary supplements. They are not FDA-approved for human use and cannot legally be marketed as drugs, foods, or supplements. Buying them for personal human consumption sits in a regulatory gray area, and purity is not guaranteed.

Do SLU-PP-332 and 5-amino-1MQ need to be cycled?

There is no clinical evidence to support any cycling protocol for either compound. Rodent studies did not establish human dosing intervals, half-life in people, or long-term safety. Any cycling schedule found online is speculative rather than evidence-based.